San Diego’s Cue Health, which went public last year in an IPO valued at nearly $3 billion, is laying off 170 manufacturing employees, due to “economic challenges” and cuts to government funding for ...
In case you missed it, this commercial for Cue COVID tests made its debut during the Super Bowl. Cue lab-quality COVID-19 tests are at-home, molecular tests that need no prescription or special ...
San Diego COVID-19 test maker Cue Health – once worth $2.3B – lays off entire company and shuts down
Cue Health, the once high-flying San Diego biotech supplying rapid COVID-19 test kits to the NBA and Google, is laying off all employees and shutting down on Friday. Cue’s closure comes a week after ...
Scaling is difficult for any company. But when your business is primed for Covid-19, growth can be as viral as the disease. That’s the case for Cue Health, a San Diego-based health care technology ...
SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), a healthcare technology company, today announced that its direct-to-consumer (DTC) virtual health platform will launch on ...
SAN DIEGO, March 16, 2022 /PRNewswire/ -- Cue Health ("Cue") (Nasdaq: HLTH), the healthcare technology company behind the most accurate at-home COVID-19 test* in the U.S., today announced that its ...
SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced ...
If so inclined, an NBA player now could test himself for the coronavirus and get results on his phone in no more than 20 minutes. And the league is convinced those tests are fast enough and accurate ...
SAN DIEGO, Feb. 23, 2021 /PRNewswire/ -- Cue Health Inc. (Cue), a healthcare technology company, today announced its molecular point-of-care COVID-19 Test has received the CE mark, clearing it for ...
Covid-19 test maker Cue Health went public on Friday at a valuation of nearly $2.3 billion. Shares opened above the $16 price set the night before and closed at $20—a 25% increase in the first day of ...
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home. Developed by Cue Health, the Cue ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback